No clue how people think schools will stay open. They'll be full online by mid-September. This thing is here to stay until we get a vaccine. Spain eased up restrictions and they've shot back up, tripling their rate over the past three weeks. Australia nearly had it eliminated and they've got an outbreak. And those are countries who actively worked together for months to eliminate the virus, to say nothing of the US right now, which is a disaster area.
The only good news I can impart is that the Oxford phase two research is excellent. The vaccine produces both antibodies and T-Cells (particularly the CD8+ cells) which means that part of it works i.e. the vaccine does what it should do, although we do not yet know if it successfully fights the virus yet, we'll find that out in phase three trials. Also, as importantly, it's SAFE. The side-effects associated with it in this trial (1,077 participants) were the usual flu vaccine side-effects such as fever, headache, muscle pain and all can be safely treated with a couple Tylenol, literally nothing serious beyond those, although this is also something they look for in phase three. Now in phase three they will test the large-scale efficacy and really look at if it's going to work fighting the virus and how long antibodies will remain, we may be getting boosters of this until/if a long-term solution is found or this could also be a two-and-done (this particular vaccine will be a shot and then a booster a month later). If we're lucky and this one is good to go then we can see good things come by year's end or Q1 2021 because many governments have been pumping billions into ramping up production for this thing, the assembly lines are waiting for the green light.
I really do think we're on the verge of great news with this thing (the phase two news above is extremely good, can't undersell it) but I do think sacrifices will continue to need to be made until then and that may be another 6-8 months.
Here's the Oxford vaccine research in The Lancet
https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)31604-4/fulltext#seccestitle10